Abstract:Proteomics is playing an increasingly important role in determining Alzheimer's disease risk, with a particular goal in identifying markers of risk before the disease manifests itself clinically. The traditional analysis methods, however, have not been able to fully capitalize on the richness of genetic data. Machine learning analytic methods provide a novel automated, scalable and less subjective approach from which to identify unique targets. The study used proteomic and clinical data from a publicly available dataset that included 120 known signaling proteins measured from 259 archived plasma samples from individuals with Alzheimer's disease and non-demented controls (http://www.nature.com/nm/journal/v13/n11/suppinfo/nm1653_S1.html). We deployed a deep belief network (DBN) based method that uses an efficient training procedure that integrates unsupervised generative learning for feature discovery with a follow-up phase of supervised learning that fine tunes the features to optimize discrimination. The DBN method identified a subset of proteins (i.e. 20 proteins) that resulted in diagnostic accuracy greater than 90%, which was of almost equal predictability to computational methods that used all 120 proteins and was significantly better than classic machine learning methods, including Support Vector Machine, k-Nearest Neighbor and Back Propagation Neural Network. The resulting deep learning network indicated the weighted contribution of each protein to the final predictive model. We also found a strong relationship between ACRP30 and AD diagnosis. Our approach highlights the power of the deep learning model by addressing three application problems: disease detection, feature selection and identification of pathogenic factors. These results also found a strong link between ACRP30, an adipocyte-specific secreted protein involved in glucose metabolism, and risk for AD using a novel computational method and outperformed other machine learning approaches that were constrained by feature dimensionality and limited size data sets. This approach also simplified the measurement index required for diagnosis by identifying a much smaller subset of factors needed to achieve high diagnostic accuracy. These results also reinforced the link between metabolic risk factors and AD and suggest that apidonectin-linked pathways are a therapeutic drug target.

Identification of Antioxidant Proteins with Deep Learning from Sequence Information

Identification of Antioxidants from Sequence Information Using Naïve Bayes

Identifying Antioxidant Proteins by Using Optimal Dipeptide Compositions

DP-AOP: A novel SVM-based antioxidant proteins identifier

Identifying Antioxidant Proteins by Using Amino Acid Composition and Protein-Protein Interactions

Machine learning-based antioxidant protein identification model: Progress and evaluation

AOPM: Application of Antioxidant Protein Classification Model in Predicting the Composition of Antioxidant Drugs

Identifying Antioxidant Proteins by Combining Multiple Methods

AOPs-SVM: A Sequence-Based Classifier of Antioxidant Proteins Using a Support Vector Machine

Prediction of Antioxidant Proteins Using Hybrid Feature Representation Method and Random Forest

Development of a Machine Learning-Based Predictor for Identifying and Discovering Antioxidant Peptides Based on a New Strategy

ORS‐Pred: an Optimized Reduced Scheme‐based Identifier for Antioxidant Proteins

Rore: Robust and Efficient Antioxidant Protein Classification Via a Novel Dimensionality Reduction Strategy Based on Learning of Fewer Features

DEEP LEARNING APPLICATION IN IDENTIFYING PROTEOMIC RISK MARKERS FOR ALZHEIMER’S DISEASE

Phenotype Classification using Proteome Data in a Data-Independent Acquisition Tensor Format

DeepDigest: Prediction of Protein Proteolytic Digestion with Deep Learning

Prediction of antioxidant peptides using a quantitative structure-activity relationship predictor (AnOxPP) based on bidirectional long short-term memory neural network and interpretable amino acid descriptors

Identification of Disease-Related 2-Oxoglutarate/Fe (II)-Dependent Oxygenase Based on Reduced Amino Acid Cluster Strategy

DeepACP: A Novel Computational Approach for Accurate Identification of Anticancer Peptides by Deep Learning Algorithm

A Novel Framework for the Identification of Drug Target Proteins: Combining Stacked Auto-Encoders with a Biased Support Vector Machine.

Protein identification with deep learning: from abc to xyz